Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
NCT ID: NCT06221423
Last Updated: 2024-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2020-01-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fruquintinib in the Cross-line Treatment of Refractory mCRC
NCT06099314
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
NCT06202417
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
NCT05634590
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
NCT06118762
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT02196688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fru plus TAS-102
mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
Fruquintinib Combined With TAS-102
Fruquintinib Combined With TAS-102
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fruquintinib Combined With TAS-102
Fruquintinib Combined With TAS-102
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
* Fruquintinib administered as salvage treatment
* Age: 18-75 years old
* Informed consent
Exclusion Criteria
* Fruquintinib and/or TAS-102 administration as second-line treatment
* Drug administration stopped after less than two cycles
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xu jianmin
Director of Colorectal Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianmin Xu
Role: PRINCIPAL_INVESTIGATOR
Department of Colorectal Surgery, Zhongshan Hospital, Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Fru plus TAS-102 in mCRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.